Table 3.
First postbaseline antineoplastic treatment received (intention-to-treat population)
| Treatment | Enzalutamide (n = 872) | Placebo (n = 845) | Total (N = 1717) |
|---|---|---|---|
| Nonswitchers (n = 981) | |||
| Docetaxel | 228 (26.1) | 401 (47.5) | 629 (36.6) |
| Hormonal | 11 (1.3) | 16 (1.9) | 27 (1.6) |
| Antiandrogen | 14 (1.6) | 45 (5.3) | 59 (3.4) |
| Switchers (n = 309)a | |||
| Enzalutamide | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Abiraterone | 61 (7.0) | 90 (10.7) | 151 (8.8) |
| Cabazitaxel | 14 (1.6) | 22 (2.6) | 36 (2.1) |
| Sipuleucel-T | 10 (1.1) | 9 (1.1) | 19 (1.1) |
| Investigational | 28 (3.2) | 43 (5.1) | 71 (4.1) |
| Other chemotherapy: cytotoxic | 14 (1.6) | 14 (1.7) | 28 (1.6) |
| Other chemotherapy: noncytotoxic | 1 (0.1) | 2 (0.2) | 3 (0.2) |
Data are presented in the table as the number of patients, with the percentages these numbers represent given in parentheses, based on the number of patients in the intention-to-treat population
aTreatments listed for ‘Switchers’ in this table are considered NOT to be part of the standard treatment pathway in the UK